NCT02699073已完成2 期
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib. A GERCOR Phase II Study
GERCOR - Multidisciplinary Oncology Cooperative Group8 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2016年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
- 试验地点
- 8
- 主要终点
- Tumor response rate at 2 months according Choi Criteria
研究概览
简要总结
The purpose of the study is to evaluate the performance of various tumor response criteria (Choi and RECIST1.1 criteria) in the assessment of regorafenib activity.
Moreover, an assessment of the tumor heterogeneity will be made using computed tomographic texture analysis (CTTA)
详细描述
This is a phase II study in patients with metastatic colorectal cancer treated by regorafenib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent.
- •Patients with histologically proven metastatic colorectal cancer
- •Patients previously treated with, or who are not considered candidates for available therapies, i.e., fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy (if patients were RAS wild-type).
- •ECOG PS = 0 or 1
- •Aged 18-years or older
- •Life expectancy of at least 3 months
- •Adequate renal, bone marrow, liver and pancreatic functions:
- •Estimated creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft-Gault equation
- •Platelet count ≥ 100.000/mm3; hemoglobin ≥ 9 g/dL; absolute neutrophil count ≥ 1500/mm
- •Transfusion to meet the inclusion criteria will not be allowed
- •Total bilirubin ≤ 1.5 the upper limit of normal value (ULN); alanine aminotransferase (ALAT) and aspartame aminotransferase (ASAT) ≤ 3.0 x ULN (≤ 5.0 x ULN for patients with liver involvement of their cancer); alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 5.0 x ULN for patients with liver involvement of their cancer and/or have bone metastases)
- •International normalized ratio (INR) ≤ 1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless receiving treatment with therapeutic anticoagulation. Patients being treated with anticoagulant, e.g., heparin, will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluation will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care
- •At least one target lesion on CT scan
- •No contraindication to Iodine contrast media injection during CT.
- •For women of childbearing potential, blood or urine pregnancy test performed a maximum of 7 days before start of study treatment and negative result documented before start of study treatment
- •When applicable, i.e., women of childbearing potential having sexual activity, men having sexual activity, must agree to use an adequate contraception before entering the study, until at least 8 weeks after the last study drug administration
- •Registration in a national health care system (CMU included).
排除标准
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion in the trial ; planned surgical procedure within the first month of treatment or any procedure that might change the timing of regorafenib administration during the first month of treatment
- •Patients under judicial protection (curatorship, tutorship) and/or deprived of freedom
- •Major surgical procedure, open biopsy or significant traumatic injury within 28 days before start of study medication
- •Pregnancy or breastfeeding
- •Congestive heart failure ≥ New York Heart Association (NYHA) class 2
- •Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
- •Myocardial infarction less than 6 months before the start of study medication
- •Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted)
- •Uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic pressure >90 mmHg despite optimal medical management)
- •Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication
- •Pleural effusion or ascites that causes respiratory compromise (≥ CTCAE grade 2, NCI-CTCAE v 4.0 dyspnea)
- •Ongoing infection >grade 2, NCI- CTCAE v 4.0
- •Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to inclusion, except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
- •Known history of human immunodeficiency virus (HIV) infection
- •Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy
- •Patients with seizure disorder requiring medication
- •History of organ allograft
- •Patients with evidence or history of any bleeding diathesis, irrespective of severity
- •Any hemorrhage or bleeding event ≥ Grade 3, NCI-CTCAE v 4.0 within 4 weeks prior to the start of study medication
- •Non-healing wound, non-healing ulcer or non-healing bone fracture
- •Dehydration grade ≥1, NCI-CTCAE v 4.0
- •Known hypersensitivity to the study drug, study drug classes or excipient in the formulation
- •Interstitial lung disease with ongoing signs or symptoms at the time of inclusion
- •Persistent proteinuria >3.5 g/24 hour measured by urine protein-creatinine ratio from a random urine sample (≥ Grade 3, NCI-CTCAE v 4.0)
- •Patients unable to swallow oral medication
- •Any malabsorption condition
- •Unresolved toxicity higher than Grade 1, NCI-CTCAE v 4.0, attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neuropathy
- •Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 3 weeks
- •Treatment with any other investigational medicinal product within 28 days prior to study entry
- •Chronic treatment potentially interacting with the study medication, i.e. strong CYP3A4 inducers/inhibitors, strong UGT1A9 inhibitors
研究组 & 干预措施
Regorafenib
Experimental
dose of regorafenib : 160mg once daily
干预措施: regorafenib (Drug)
结局指标
主要结局
Tumor response rate at 2 months according Choi Criteria
时间窗: 2 months after the beginning of treatment
次要结局
- Progression free survival (PFS)(PFS is the time from the date of study drug start to the date of progressive disease or death due to any cause, up to 36 months)
- Tumor response rate at 1 and 2 months according to RECIST1.1(At 1 month and 2 months after the beginning of treatment)
- Tumor response rate at 1 month according to Choi criteria(At 1 month after the beginning of treatment)
- Best overall response rate (BOR) according to Choi criteria and to RECIST 1.1(BOR is the best response recorded from the strat of treatment until treatment failure up to 36 months)
- Disease control rate (DCR)(DCR is the proportion of patient with tumor response (CR or RP) or tumor stabilization as best response from the inclusion until treatment failure, up to 36 months)
- Overall Survival (OS)(Assessed from the date of study drug start to the date of patient death, due to any cause or to the last date the patient was known to be alive, up to 36 months)
- Specificity of Choi criteria at 1 month in identifying patients with long or short OS (using median OS as cut-off value).(At 1 month after inclusion)
- Evaluation of tumor heterogeneity with TexRAD software(At baseline and 1 month after inclusion)
- Serious adverse events( SAE) and adverse event (AE)(Up to 36 months)
- Identify early prognostic biomarkers of regorafenib(at baseline, Cycle 1 Day 15, cycle 2 Day 15 and end of treatment)
- Correlation between Baseline cell free DNA and survival outcomes (PFS and OS)(at baseline, Cycle 1 Day 15, cycle 2 Day 15 and end of treatment)
研究者
研究点 (8)
Loading locations...
相似试验
撤回
不适用
Evaluation of tumor response during and after (chemo)radiotherapy for patients with oropharyngeal squamous cell carcinoma using functional imaging by diffusion-weighted MRIOropharynx cancerthroat cancer10027655NL-OMON38623Erasmus MC, Universitair Medisch Centrum Rotterdam40
已完成
2 期
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular LymphomaNon-Hodgkin LymphomaNCT00177554University of Pittsburgh60
已完成
2 期
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLCCarcinoma, Non-Small-Cell LungNCT00252382Sunesis Pharmaceuticals31
Unknown
不适用
MRI for Selection of Complete Responders After Chemoradiation for Locally Advanced Rectal CancerCancer, RectumNCT04790227Assiut University50
终止
2 期
Study in Locally Advanced Squamous Cell Carcinoma of Head and NeckHead and Neck CancerNCT01133678University of Chicago50